Background: Autism spectrum conditions (ASC) are defined by criteria comprising impairments in social interaction and communication. Altered visual perception is one possible and often discussed cause of difficulties in social interaction and social communication. Recently, Ashwin et al. suggested that enhanced ability in local visual processing in ASC was due to superior visual acuity, but that study has been the subject of methodological criticism, placing the findings in doubt.
Methods: The present study investigated visual acuity thresholds in 24 adults with Asperger's syndrome and compared their results with 25 control subjects with the 2 Meter 2000 Series Revised ETDRS Chart.
Results: The distribution of visual acuities within the two groups was highly similar, and none of the participants had superior visual acuity.
Conclusions: Superior visual acuity in individuals with Asperger's syndrome could not be established, suggesting that differences in visual perception in ASC are not explained by this factor. A continued search for explanations of superior ability in local visual processing in persons with ASC is therefore warranted.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.biopsych.2011.07.025 | DOI Listing |
Eye Contact Lens
January 2025
Department of Ophthalmology (B.S., A.S., S.B., J.K.), Emory University School of Medicine, Atlanta, GA; and Emory University School of Medicine (S.C.), Atlanta, GA.
Purpose: Symptom management in Ocular Cicatricial Pemphigoid (OCP) is challenging because of the progressive factors of dry eye, scarring, trichiasis, and vision impairment. We set out to evaluate the benefits and therapeutic effects of scleral contact lenses in the management of OCP.
Methods: A retrospective review was performed over a database of 20 patients (36 eyes) fitted with scleral lenses (SL) at the Department of Ophthalmology, Emory University from May 2018 to April 2021.
Vopr Kurortol Fizioter Lech Fiz Kult
January 2025
Russian University of Medicine of the Ministry of Health of the Russian Federation, Moscow, Russia.
Objective: To evaluate the effectiveness of a treatment complex including magnetophoresis with the drug «Argensept» and tear therapy in patients with mild to moderate dry eye syndrome.
Material And Methods: The study was conducted on 50 people (100 eyes) diagnosed with mild to moderate dry eye syndrome (H04.1 according to ICD-10).
Cureus
December 2024
Ophthalmology, Faculty of Medicine, Alanya Alaaddin Keykubat University, Antalya, TUR.
Purpose This study evaluated the efficacy of oral melatonin therapy for visual acuity and retinal and choroidal structures in patients with chronic central serous chorioretinopathy (CSCR). Methods Fourteen patients with CSCR were included; eight received oral melatonin (3 mg nightly), and six formed the control group. Best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), and choroidal vascularity index (CVI) were assessed at baseline and after one month.
View Article and Find Full Text PDFCureus
December 2024
Department of Ophthalmology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Jeddah, SAU.
Optic nerve disorders significantly contribute to visual impairment with irreversible visual deficits. Current treatments have limited efficacy in resolving chronic visual deficits, necessitating novel therapeutic strategies. Neurorehabilitation techniques, including repetitive transorbital alternating current stimulation (rtACS), have emerged as promising approaches to restore lost visual function through the ability to modulate brain activity.
View Article and Find Full Text PDFFront Med (Lausanne)
January 2025
Eye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences University of Campania "Luigi Vanvitelli", Naples, Italy.
Background: Age-related macular degeneration (AMD) is a prevalent cause of irreversible vision loss worldwide, particularly among the elderly population. Two forms of late AMD are described: neovascular AMD (nAMD), characterized by abnormal choroidal blood vessel growth, and atrophic (dry) AMD, involving retinal cell degeneration. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents have transformed nAMD treatment, with Brolucizumab emerging as a promising therapy.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!